Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: A systematic review and meta-analysis

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  He, Lei ^a   Deng, Linfeng ^a   Zhang, Quan ^b   Guo, Jianli ^a   Zhou, Jinan ^a   Song, Wenjian ^c   Yuan, Fahu ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hubei Provincial Hospital of Integrated Chinese and Western Medicine   (China)

^c JIANGHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; FIBROBLAST GROWTH FACTOR 21; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

CLINICAL EVALUATION; COCHRANE LIBRARY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EMBASE; EVIDENCE BASED PRACTICE; HUMAN; MEDLINE; META ANALYSIS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; WEB OF SCIENCE; BIOPSY; BLOOD; FATTY LIVER; LIVER; PATHOLOGY;

BIOMARKERS; BIOPSY; FATTY LIVER; FIBROBLAST GROWTH FACTORS; HUMANS; KERATIN-18; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85018572928     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/9729107     Document Type: Review

References (58)

1. G. Marchesini, E. Bugianesi, G. Forlani et al., "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome," Hepatology, vol. 37, no. 4, pp. 917-923, 2003.
2. E. Fabbrini, S. Sullivan, and S. Klein, "Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications," Hepatology, vol. 51, no. 2, pp. 679-689, 2010.
3. S. Chitturi, G. C. Farrell, and J. George, "Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?" Journal of Gastroenterology and Hepatology (Australia), vol. 19, no. 4, pp. 368-374, 2004.
4. G. A. Michelotti, M. V. Machado, and A. M. Diehl, "NAFLD, NASH and liver cancer," Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 11, pp. 656-665, 2013.
5. M. S. Ascha, I. A. Hanouneh, R. Lopez, T. A.-R. Tamimi, A. F. Feldstein, and N. N. Zein, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis," Hepatology, vol. 51, no. 6, pp. 1972-1978, 2010.
6. J. Ertle, A. Dechêne, J.-P. Sowa et al., "Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis," International Journal of Cancer, vol. 128, no. 10, pp. 2436-2443, 2011.
7. A. Wieckowska, A. J. McCullough, and A. E. Feldstein, "Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future," Hepatology, vol. 46, no. 2, pp. 582-589, 2007.
8. D. E. Amacher, "Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease," Biomarkers, vol. 19, no. 7, pp. 541-552, 2014.
9. R. Kwok, Y.-K. Tse, G. L.-H. Wong et al., "Systematic reviewwith meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments," Alimentary Pharmacology andTherapeutics, vol. 39, no. 3, pp. 254-269, 2014.
10. J. Chen, Y. Y. Zhu, Q. Zheng, and J. J. Jiang, "Serumcytokeratin- 18 in the diagnosis of non-alcoholic steatohepatitis: a metaanalysis," Hepatology Research, vol. 44, no. 8, pp. 854-862, 2014.
11. A. Wieckowska, N. N. Zein, L. M. Yerian, A. R. Lopez, A. J. McCullough, and A. E. Feldstein, "In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease," Hepatology, vol. 44, no. 1, pp. 27-33, 2006.
12. Y. Yilmaz, E. Dolar, E. Ulukaya et al., "Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis," World Journal of Gastroenterology, vol. 13, no. 6, pp. 837-844, 2007.
13. D. L. Diab, L. Yerian, P. Schauer et al., "Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients," Clinical Gastroenterology and Hepatology, vol. 6, no. 11, pp. 1249-1254, 2008.
14. A. E. Feldstein, A. Wieckowska, A. R. Lopez, Y.-C. Liu, N. N. Zein, and A. J. McCullough, "Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study," Hepatology, vol. 50, no. 4, pp. 1072-1078, 2009.
15. G. V. Papatheodoridis, E. Hadziyannis, E. Tsochatzis et al., "Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease," Journal of Clinical Gastroenterology, vol. 44, no. 4, pp. E87-E95, 2010.
16. G. Musso, R. Gambino, M. Durazzo, and M. Cassader, "Noninvasive assessment of liver disease severity with liver fat score andCK-18 inNAFLD: prognostic value of liver fat equation goes beyond hepatic fat estimation," Hepatology, vol. 51, no. 2, pp. 715-717, 2010.
17. R. Malik, M. Chang, K. Bhaskar et al., "The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease," Journal of Gastroenterology andHepatology, vol. 24, no. 4, pp. 564-568, 2009.
18. J. Shen, H. L.-Y. Chan, G. L.-H. Wong et al., "Assessment of non-alcoholic fatty liver disease using serumtotal cell death and apoptosis markers," Alimentary Pharmacology & Therapeutics, vol. 36, no. 11-12, pp. 1057-1066, 2012.
19. D. Joka, K. Wahl, S. Moeller et al., "Prospective biopsycontrolled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis," Hepatology, vol. 55, no. 2, pp. 455-464, 2012.
20. Z. M. Younossi, M. Jarrar, C. Nugent et al., "A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)," Obesity Surgery, vol. 18, no. 11, pp. 1430-1437, 2008.
21. Z. M. Younossi, S. Page, N. Rafiq et al., "A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis," Obesity Surgery, vol. 21, no. 4, pp. 431-439, 2011.
22. I. Pirvulescu, L. Gheorghe, I. Csiki et al., "Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery," Chirurgia (Bucharest, Romania : 1990), vol. 107, no. 6, pp. 772-779, 2012.
23. M. Grigorescu, D. Crisan, C. Radu, M. D. Grigorescu, Z. Sparchez, and A. Serban, "A novel pathophysiologicalbased panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis," Journal of Physiology and Pharmacology, vol. 63, no. 4, pp. 347-353, 2012.
24. J. Y. Shen, H. L.-Y. Chan, G. L.-H. Wong et al., "Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers," Journal of Hepatology, vol. 56, no. 6, pp. 1363-1370, 2012.
25. Y. Yilmaz and F. Eren, "Identification of a support vector machine-based biomarker panelwith high sensitivity and specificity for nonalcoholic steatohepatitis," Clinica Chimica Acta, vol. 414, pp. 154-157, 2012.
26. M. Yang, D. Xu, Y. Liu et al., "Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis," PLOS ONE, vol. 10, no. 6, Article IDe0131664, 2015.
27. Y. Yilmaz, F. Eren, O. Yonal et al., "Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease," European Journal of Clinical Investigation, vol. 40, no. 10, pp. 887-892, 2010.
28. H. T. Li, Q. C. Fang, F. Gao et al., "Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride," Journal of Hepatology, vol. 53, no. 5, pp. 934-940, 2010.
29. J. Dushay, P. C. Chui, G. S. Gopalakrishnan et al., "Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease," Gastroenterology, vol. 139, no. 2, pp. 456-463, 2010.
30. S. Dasarathy, Y. Yang, A. J. McCullough, S. Marczewski, C. Bennett, and S. C. Kalhan, "Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis," European Journal of Gastroenterology & Hepatology, vol. 23, no. 5, pp. 382-388, 2011.
31. T. Reinehr, J. Woelfle, R. Wunsch, and C. L. Roth, "Fibroblast Growth Factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis," Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 6, pp. 2143-2150, 2012.
32. H. Li, K. Dong, Q. Fang et al., "High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China," Journal of Hepatology, vol. 58, no. 3, pp. 557-563, 2013.
33. Y. Shen, X. Ma, J. Zhou et al., "Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease," Cardiovascular Diabetology, vol. 12, no. 1, article 124, 2013.
34. C. Giannini, A. E. Feldstein, N. Santoro et al., "Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage," Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 7, pp. 2993-3000, 2013.
35. A. Alisi, S. Ceccarelli, N. Panera et al., "Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease," PLoS ONE, vol. 8, no. 6, Article ID e67160, 2013.
36. N. Panic, E. Leoncini, G. De Belvis, W. Ricciardi, and S. Boccia, "Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses," PLOS ONE, vol. 8, no. 12, 2013.
37. P. F. Whiting, A.W. S. Rutjes, M. E. Westwood et al., "Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies," Annals of InternalMedicine, vol. 155, no. 8, pp. 529-536, 2011.
38. H. Sahai and A. Khurshid, "On analysis of epidemiological data involving a 2×2 contingency table: an overview of fisher's exact test and yates' correction for continuity," Journal of Biopharmaceutical Statistics, vol. 5, no. 1, pp. 43-70, 1995.
39. A. Wree, L. Broderick, A. Canbay, H. M. Hoffman, and A. E. Feldstein, "From NAFLD to NASH to cirrhosis-new insights into disease mechanisms," Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 11, pp. 627-636, 2013.
40. I. Nalbantoglu and E. M. Brunt, "Role of liver biopsy in nonalcoholic fatty liver disease," World Journal of Gastroenterology, vol. 20, no. 27, pp. 9026-9037, 2014.
41. H. Bantel, P. Ruck, M. Gregor, and K. Schulze-Osthoff, "Detection of elevated caspase activation and early apoptosis in liver diseases," European Journal of Cell Biology, vol. 80, no. 3, pp. 230-239, 2001.
42. Y. C. Woo, A. M. Xu, Y. Wang, and K. S. L. Lam, "Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives," Clinical Endocrinology, vol. 78, no. 4, pp. 489-496, 2013.
43. F. M. Fisher, P. C. Chui, P. J. Antonellis et al., "Obesity is a fibroblast growth factor 21 (FGF21)-resistant state," Diabetes, vol. 59, no. 11, pp. 2781-2789, 2010.
44. H. Yan, M. Xia, X. Chang et al., "Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study," PLoS ONE, vol. 6, no. 9, 2011.
45. G. C. Farrell and C. Z. Larter, "Nonalcoholic fatty liver disease: from steatosis to cirrhosis," Hepatology, vol. 43, no. 2, pp. S99- S112, 2006.
46. Y. Yilmaz, E. Ulukaya, and E. Dolar, "A 'biomarker biopsy' for the diagnosis of NASH: promises from CK-18 fragments," Obesity Surgery, vol. 18, no. 11, pp. 1507-1508, 2008.
47. P. Mofrad, M. J. Contos, M. Haque et al., "Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values," Hepatology, vol. 37, no. 6, pp. 1286-1292, 2003.
48. S. S. Kunde, A. J. Lazenby, R. H. Clements, and G. A. Abrams, "Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women," Hepatology, vol. 42, no. 3, pp. 650-656, 2005.
49. A. J. Sanyal, "Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease," Nature Clinical Practice Gastroenterology and Hepatology, vol. 2, no. 1, pp. 46-53, 2005.
50. H. Hetz, K. Hoetzenecker, S. Hacker et al., "Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration," Journal of Clinical Laboratory Analysis, vol. 21, no. 5, pp. 277- 281, 2007.
51. A. Wree, A. Kahraman, G. Gerken, and A. Canbay, "Obesity affects the liver-the link between adipocytes and hepatocytes," Digestion, vol. 83, no. 1-2, pp. 124-133, 2011.
52. A. Wree, L. Broderick, A. Canbay, H. M. Hoffman, and A. E. Feldstein, "From NAFLD to NASH to cirrhosis-new insights into diseasemechanisms," Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 11, pp. 627-636, 2013.
53. A. Wree, M. Schlattjan, L. P. Bechmann et al., "Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients, "Metabolism: Clinical and Experimental, vol. 63, no. 12, pp. 1542-1552, 2014.
54. P. Eusebi, "Diagnostic accuracy measures," Cerebrovascular Diseases, vol. 36, no. 4, pp. 267-272, 2013.
55. P. Valva, E. De Matteo, M. C. Galoppo, M. I. Gismondi, and M. V. Preciado, "Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis," Journal of Medical Virology, vol. 82, no. 6, pp. 949-957, 2010.
56. J. Xu, D. J. Lloyd, C. Hale et al., "Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice," Diabetes, vol. 58, no. 1, pp. 250-259, 2009.
57. T. Inagaki, P. Dutchak, G. Zhao et al., "Endocrine regulation of the fasting response by pparα-mediated induction of fibroblast growth factor 21," Cell Metabolism, vol. 5, no. 6, pp. 415-425, 2007.
58. H. Y. Yu, F. Z. Xia, K. S. L. Lam et al., "Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans," Clinical Chemistry, vol. 57, no. 5, pp. 691-700, 2011.